Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 3,035 shares at $201.27 ($614K) on 2021-07-13, disclosed to the SEC on 2021-07-22.
Open-market sale of $614k RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $201.27 | 441 | $89K | 14.5% |
| 2 | $201.27 | 441 | $89K | 14.5% |
| 3 | $202.29 | 630 | $127K | 20.8% |
| 4 | $202.29 | 630 | $127K | 20.8% |
| 5 | $203.09 | 444 | $90K | 14.7% |
| 6 | $203.09 | 444 |
| $90K |
| 14.7% |
| 7 | $204.02 | 5 | $1K | 0.2% |
| Total | $202.23 avg | 3,035 | $614K | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |